Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521686 · ClinicalTrials.gov registry record · Phase 1
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
A Phase 1 study of Glioma and Cholangiocarcinoma, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04521686 is a Phase 1 study of Glioma and Cholangiocarcinoma that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 200 participants, roughly in line with the 208-participant average among 87 other Glioma trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT04521686, a Phase 1 study of Glioma and Cholangiocarcinoma, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Durvalumab
- DRUG LY3410738
Study Locations (20)
New York
- Memorial Sloan Kettering Cancer Center - Commack
- Memorial Sloan Kettering Cancer Center - Harrison
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic of Scottsdale - Phoenix
- The University of Arizona Cancer Center - Tucson
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Texas
- University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Other
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
- Gustave Roussy - Villejuif
California
- USC Norris Cancer Hospital - Los Angeles
Florida
- Mayo Clinic in Florida - Jacksonville
Illinois
- University of Chicago Pritzker School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04521686
The ClinicalTrials.gov registry entry for NCT04521686 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 208-participant average among 87 other Glioma trials with a reported enrollment target. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.
NCT04521686 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04521686 about?
NCT04521686 is a clinical study titled "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations". This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and gliom...
What is the current status of trial NCT04521686?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2020-10-01. Estimated completion is 2026-05.
What conditions does trial NCT04521686 study?
This clinical trial studies the following conditions: Glioma, Cholangiocarcinoma, Chondrosarcoma, Any Solid Tumor.
What interventions are being tested in trial NCT04521686?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Durvalumab (DRUG), LY3410738 (DRUG).
Who is sponsoring clinical trial NCT04521686?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04521686 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.